JP2023513901A - タウオパチーの治療方法 - Google Patents

タウオパチーの治療方法 Download PDF

Info

Publication number
JP2023513901A
JP2023513901A JP2022548978A JP2022548978A JP2023513901A JP 2023513901 A JP2023513901 A JP 2023513901A JP 2022548978 A JP2022548978 A JP 2022548978A JP 2022548978 A JP2022548978 A JP 2022548978A JP 2023513901 A JP2023513901 A JP 2023513901A
Authority
JP
Japan
Prior art keywords
deuterated
optionally substituted
acid
ester
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513901A5 (https=
Inventor
シチェピノフ、ミハイル、セルゲーエヴィチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Retrotope Inc
Original Assignee
Retrotope Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrotope Inc filed Critical Retrotope Inc
Publication of JP2023513901A publication Critical patent/JP2023513901A/ja
Publication of JP2023513901A5 publication Critical patent/JP2023513901A5/ja
Priority to JP2025202414A priority Critical patent/JP2026035680A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022548978A 2020-02-14 2021-02-12 タウオパチーの治療方法 Pending JP2023513901A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025202414A JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976958P 2020-02-14 2020-02-14
US62/976,958 2020-02-14
PCT/US2021/017981 WO2021163580A1 (en) 2020-02-14 2021-02-12 Methods for treating tauopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025202414A Division JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Publications (2)

Publication Number Publication Date
JP2023513901A true JP2023513901A (ja) 2023-04-04
JP2023513901A5 JP2023513901A5 (https=) 2024-02-20

Family

ID=77273602

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548978A Pending JP2023513901A (ja) 2020-02-14 2021-02-12 タウオパチーの治療方法
JP2025202414A Pending JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025202414A Pending JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Country Status (9)

Country Link
US (2) US20210251933A1 (https=)
EP (1) EP4103169A4 (https=)
JP (2) JP2023513901A (https=)
KR (1) KR20220140808A (https=)
CN (1) CN116507325A (https=)
AU (1) AU2021220981A1 (https=)
CA (1) CA3171330A1 (https=)
IL (1) IL295512A (https=)
WO (1) WO2021163580A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
WO2022170134A2 (en) * 2021-02-05 2022-08-11 Retrotope, Inc. Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof
US11491130B2 (en) * 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
KR20240055796A (ko) * 2021-09-03 2024-04-29 바이오지바 엘엘씨 중수소화 pufa를 이용한 세포 기능장애 및 세포 사멸의 억제를 위한 방법, 시스템 및 조성물
IL313592A (en) * 2021-12-21 2024-08-01 Biojiva Llc Methods and preparations for the treatment of inflammatory disease
WO2023192406A2 (en) * 2022-03-30 2023-10-05 Retrotope, Inc. Prophylactic methods for treating als

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509439A (ja) * 2009-10-30 2013-03-14 レトロトップ、 インコーポレイテッド Ｐｕｆａ誘導体による酸化ストレス障害の緩和
JP2014513098A (ja) * 2011-04-26 2014-05-29 レトロトップ、 インコーポレイテッド 神経変性障害および筋疾患に関与するｐｕｆａ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012148930A2 (en) * 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
CN110167546A (zh) * 2016-11-17 2019-08-23 乐巢拓普有限公司 同位素修饰的组分及其治疗用途
EP3461479B1 (en) * 2017-09-27 2021-06-16 Julie Blivet Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions
JP2021527648A (ja) * 2018-06-15 2021-10-14 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の低減

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509439A (ja) * 2009-10-30 2013-03-14 レトロトップ、 インコーポレイテッド Ｐｕｆａ誘導体による酸化ストレス障害の緩和
JP2014513098A (ja) * 2011-04-26 2014-05-29 レトロトップ、 インコーポレイテッド 神経変性障害および筋疾患に関与するｐｕｆａ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHMED ELHARRAM ET AL., THE FEBS JOURNAL, vol. 284, JPN6025004854, 2017, pages 4083 - 4095, ISSN: 0005795512 *
LUC BUEE AND ANDRE DELACOURTE, BRAIN PATHOLOGY, vol. 9, JPN6025004853, pages 681 - 693, ISSN: 0005795513 *
SOPHIA M.RAEFSKY ET AL., NEUROBIOL AGING, vol. 66, JPN6025004855, 2018, pages 165 - 176, ISSN: 0005795511 *

Also Published As

Publication number Publication date
WO2021163580A1 (en) 2021-08-19
US20250177339A1 (en) 2025-06-05
CN116507325A (zh) 2023-07-28
US20210251933A1 (en) 2021-08-19
CA3171330A1 (en) 2021-08-19
JP2026035680A (ja) 2026-03-04
EP4103169A1 (en) 2022-12-21
IL295512A (en) 2022-10-01
AU2021220981A1 (en) 2022-09-22
KR20220140808A (ko) 2022-10-18
EP4103169A4 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
JP2023513901A (ja) タウオパチーの治療方法
Besouw et al. Cysteamine: an old drug with new potential
US11759469B2 (en) Administration and dosage of diaminophenothiazines
EP2442647B1 (en) Dithiol compounds, derivatives, and uses therefor
US20250215026A1 (en) Deuterated Compounds, Compositions and Uses
US12251373B2 (en) Compounds and methods of treating retinal degeneration
ES2812800T3 (es) Nuevos usos terapéuticos de derivados de la bencilidenguanidina para el tratamiento de proteopatías
JP7296472B2 (ja) プリドピジンを使用したミトコンドリア関連疾患および障害（それらの症状を含む）の治療
RS57624B1 (sr) Nova sukcinatna jedinjenja koja prodiru u ćelije
TW202045150A (zh) PPARẟ促效劑於治療脂肪酸氧化異常(FAOD)之用途
WO2008060332A2 (en) Methods for treating or reducing muscle fatigue
JP2012514032A (ja) ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物
EP3187185A1 (en) Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound
ES2959243T3 (es) Nuevo tratamiento de enfermedades mitocondriales
GB2548839A (en) New uses and methods
EP2522394B1 (en) Substituted phosphonates and their use decreasing amyloid aggregates
JP7598195B2 (ja) 肥満及び関連する障害の予防及び治療のための化合物
CA3056873A1 (en) Derivatives of sulindac can protect normal cells against oxidative damage
HK40106579B (en) Administration and dosage of diaminophenothiazines
HK1229161A (en) Dithiol compounds, derivatives, and uses therefor
HK1229161A1 (en) Dithiol compounds, derivatives, and uses therefor
BR112016023086B1 (pt) Composto, composição, e, uso de um composto

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251125